Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 13/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.31 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26128380 | 1.00 | PDK1 (0.45) | PDK1DRD4L3MBTL1DRD2DRD3 | |
| SCHEMBL14835269 | 0.90 | PDK1 (0.42) | PDK1DRD4L3MBTL1DRD2DRD3 | |
| SCHEMBL14836102 | 0.90 | PDK1 (0.42) | PDK1DRD4L3MBTL1DRD2DRD3 | |
| SCHEMBL14835270 | 0.90 | PDK1 (0.42) | PDK1DRD4L3MBTL1DRD2DRD3 | |
| SCHEMBL3029708 | 0.85 | PDK1 (0.61) | PDK1L3MBTL1PIK3CDPIK3R2PIK3CA | |
| SCHEMBL571075 | 0.85 | PDK1 (0.61) | PDK1L3MBTL1PIK3CDPIK3R2PIK3CA | |
| SCHEMBL2934637 | 0.85 | PDK1 (0.61) | PDK1L3MBTL1PIK3CDPIK3R2PIK3CA | |
| SCHEMBL1920418 | 0.84 | PDK1 (0.40) | PDK1DRD4DRD2DRD3CYP19A1 | |
| SCHEMBL18669235 | 0.84 | PDK1 (0.40) | PDK1DRD4DRD2DRD3CYP19A1 | |
| SCHEMBL21070197 | 0.84 | PDK1 (0.40) | PDK1DRD4DRD2DRD3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-3440075-B1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| EP-3440069-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440075-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174620-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017174621-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| EP-2683697-B1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| WO-2015028409-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | WO | disclosed |
| EP-2683697-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | Lupin Limited (IN) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345213-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2013-12-26 | — | — | US | disclosed |
| WO-2012120476-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| WO-2008016811-A2 | AMINOPIPERIDINES AND REALTED COMPOUNDS | NEUROGEN CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345213-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | PDK1 4335/4885DRD4 3137/4885L3MBTL1 4554/4885 |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | PDK1 226/4885DRD4 4427/4885L3MBTL1 4308/4885 |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | PDK1 4335/4885DRD4 3137/4885L3MBTL1 4554/4885 |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | PDK1 939/4885DRD4 4122/4885L3MBTL1 4361/4885 |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | PDK1 226/4885DRD4 4427/4885L3MBTL1 4308/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PDK1 939/4885DRD4 4122/4885L3MBTL1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.